chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In 2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications used were not reported.  No treatment medication were reported.
fever 100; headache; body aches; chills; shot site pain; Flushing of face; This is a spontaneous report from a contactable consumer. This 66-year-old female consumer reported for herself that: A 66-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Batch/Lot Number were not reported), via unspecified route administration, administered in right arm on 28Feb2021 16:00 as (at the age of 66-years-old) DOSE 2, SINGLE for COVID-19 immunization. The patient medical history included high blood pressure from an unknown date and unknown if ongoing. The patient had not any allergies. The patient was not pregnant at the time of vaccination. Concomitant medication(s) included losartan (LOSARTAN) and alendronate sodium (FOSAMAX) both taken for an unspecified indication, start and stop date were not reported. The patient had not received other vaccine within four weeks, Prior to vaccination. The other medications received in two weeks Losartan Fosamax. The patient hat not covid prior vaccination. Patient had not covid tested post vaccination. The patient had previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EM9809), via unspecified route administration on 07Feb2021 16:00 as (at the age of 66-years-old) DOSE 1, SINGLE for COVID-19 immunization. On 28Feb2021 16:30 after the second dose of vaccination, the patient experienced flushing of face. On 01Mar2021 02:00 the patient experienced fever 100, headache, body aches, chills and shot site pain. It was reported that adverse event flushing of face about 1/2 hour after receiving dose. Headache, fever (100), body aches, chills, shot-site pain starting about 10 hours after receiving dose. On an unspecified date, the patient underwent lab tests and procedures which included body temperature: 100 degrees. The patient had not received treatment for the adverse events. The outcome of event fever 100 was recovered on an unspecified date, while outcome of other events was recovering at the time of last observation.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.  No further information is expected.
[after first two doses] sore arm; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA ([after first two doses] sore arm) in a 75-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A, 014F21A and 012M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA ([after first two doses] sore arm). At the time of the report, MYALGIA ([after first two doses] sore arm) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported.  No treatment medication use was reported.    This case was linked to MOD-2021-395665, MOD-2021-395653 (Patient Link).
he was a "full-blown diabetic" in an emergency situation/he wasn't diabetic until he got the shot; his sugar was "400 something"; chest pain; abdominal pain; felt awful; if he closed his eyes he would just go to sleep; This is a spontaneous report from a contactable consumer (patient's parent). A 51-year-old male patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date not reported) via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The reporter was calling in behalf of her son. The patient had the first dose of Pfizer's COVID-19 vaccine on Saturday about 2 weeks ago, does not know exact date. The next Monday, on an unspecified date, he was a "full-blown diabetic" in an emergency situation and his sugar was "400 something". The patient also experienced chest pain, abdominal pain, felt awful, and if he closed his eyes he would just go to sleep on an unspecified date. Back in Dec (year not reported), his blood sugar was 88 in a general check-up, but he was not a diabetic as far as they knew. The reporter stated that he wasn't diabetic until he got the shot. They think it was caused by the COVID shot, he was told in the emergency room not to take the 2nd shot. The outcome of the events was unknown.   Information about lot/batch number has been requested.
Patient came to pharmacy to report "itchy and tingly" arm. Patient stated her right are has been itching since she received the Shingrix vaccine. She states Benadryl does help. Patient states she will contact her MD concerning this. She was advised not to get the second dose.
temperature excursion vaccine has been administered; No additional AEs reported; This spontaneous report was received from a other reporter referring to some patients of unknown age and gender. The patients' pertinent medical histories, concomitant drugs and drug allergies were not reported.  On 02-JUL-2021, the measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (albumin status recombinant Human albumin (rHA)) had a temperature excursion. Since then, in July 2021, patients were administered with the vaccine (lot #: T012806, expiration date was reported as 14-APR-2022, dose, strength and route were not reported) for prophylaxis. No further information was available. No additional adverse events reported.  Temperature excursion of this vaccine was 14.3 degrees Celsius for 4 hours and 30 minutes without any previous temperature excursion. The digital data logger was involved in recording excursion details.
Pt recv vax on 11/30/98; on 12/6/98 pt exp infantile spasms;Annual follow-up dated 2/21/01 states no more seizure activity, but developed a mild developemntal delay.
2nd dose reactions began approximately 12 hours after initial injection. Low grade fever and no appetite. A few hours later fever spiked to 101.3, chills nausea, muscle spasms, body aches, vomiting, drenched bed from sweating. Second day: red, swollen rash and hot to touch at injection site, bad headache, nausea,  no appetite, lethargic, low grade fever that evening with night sweats. 3rd day a little nausea but overall feeling much better today.
dose administered to patient after more than 1 temperature excursion; dose administered to patient after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Apr-2021 at 10:44 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Apr-2021 at 10:44 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (dose administered to patient after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (dose administered to patient after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 70.59  Concomitant products were not provided.  On 28-Apr-2021 vials were moved to clinic. On 19-Apr-2021 the vaccines were moved to fridge. On 28-Apr-2021, the vial underwent the excursion on the following timings: at 09 AM temperature was 33.  The vaccine beyond use date was reported as 19-May-2021.  Vial was stored in cooler 1, on 28-Apr-2021, temperature excursion at 9 AM: 33 and 10 AM: 36. The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  The vial was not in a frozen state at the time of vaccine administration. It was reported that, the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The health care professional explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34- or 35-degree Fahrenheit. Treatment medications were not reported.   This case was linked to MOD-2022-566976 (Patient Link).
employee received second Hepatitis immunization at 2:10 pm and went back to work on donor floor. She started to have tightness  in chest and was feeling hot 40 minutes after immunization. she was brought to Medical office VS take BP 144/89 pulse 69, she was monitored and nurse line was called due to employee reaction to immunization. Chest tightness decreased after 45 minutes sitting in the medical office . VS BP 132/83 Pulse 85.  Nurse line instructed employee to go to Urgent care for follow up .
- About a half hour after injection, started getting some tightness in the throat  - About an hour after injection, lower lip started tingling, tongue felt dehydrated despite drinking plenty of fluids, weird metallic taste in the mouth  - Symptoms proceeded to get worse until about two and a half hours after the injection when they held at a constant level of discomfort  - Mild jaw pain about four and a half hours after injection, still have taste and throat tightness, lower lip partially numb   - Symptoms slightly improve after taking 25mg of Benadryl four and a half hours after injection (taken after jaw pain started) but don't go away  - Resting heart rate elevated (measured at 96, usually 72) about 7 hours after injection, face flushed  - Injection site red/itchy about 8 hours after injection and throat tightness returns (Benadryl may be wearing off)  - Throat tightness worsens again about 10 hours after injection, this and other symptoms mentioned except jaw pain still present remainder of the day   Day 2: tongue dehydration feeling persists and throat tightness comes and goes throughout the day   Day 3: throat tightness comes and goes throughout the day   Day 5: visit primary care physician - described the reaction and was advised to get  the J&J shot as the second dose rather than get another Pfizer shot (which I do a couple months later)
Day after vaccine : redness, warmth and swelling  at injection site  **One week plus on day after vaccine: Itching, raised warm,  firm (hard), red circle around injection site
Lack of seroconversion-negative Titer on 2/16/01; repeated on 3/23/01 (different lab)-<2.0. Had Recombivax-HB on 8/13/99 (lot 0256J) and 9/20/99 (lot 0654J).
Developed a fever the evening of 4/28 after having received the shot earlier that afternoon. The fever lasted for about 1.5 days and reached over 102 degrees F. I didn?t seek medical care, but took ibuprofen to help relieve the symptoms. I also had pain in the left arm were the shot was given, which lasted for about 2 days (only slightly sore now as I?m reporting this two days later).
This spontaneous report as received from a healthcare worker refers to an unspecified number of patients of unknown age and gender. There were no concomitant medications, concurrent conditions and medical history reported. Some doses of (Oka/Merck) VARIVAX lot# reported as L003777, exp. 04-FEB-2017, lot# K006132, exp. 29-APR-2016 and lot# reported as L002216, exp. 21-JAN-2017 (doses were not reported), which were exposed to temperatures outside of the recommended range, have been adminsitered to unspecified patients on unspecified dates since 14-AUG-2015. No adverse experience has been reported. Additional information has been requested. This is one of several reports received from the same reporter.
Father states 1 day of HA, shoulder pain and leg weakness after Menactra shot. Went to doctor and missed 1 day of school, better now on 6/9/06.
This spontaneous report was received from a nurse concerning an unknown number of patients, unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date, the patients were vaccinated with a dose of PROQUAD (dose, frequency, strength and route were not reported). Co-suspect and concomitant therapies were not reported. The nurse reported that in her facility got a new thermometer system on 13-MAY-2014, and according to the thermometer, PROQUAD was exposed to temperatures above the recommended storage temperature on multiple occasions. At this time, it was not known whether or not the excursions were supported because data was insufficient to evaluate. The nurse stated that she was certain that doses of PROQUAD had been administered to patients since these excursions were recorded. No adverse effects have been experienced. Additional information has been requested. This case is one (1) or two (2) reports from the same source.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 11Apr2022 as dose number unknown, single (Lot number: FK9893) at the age of 69 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jul2022, outcome "recovered" and all described as "COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 (Paxlovid).  Clinical course: It was reported that, the patient received other medication in two weeks. Adverse event: Bitter taste in throat. However, patient was writing because she had a positive reaction that she can only say was due to taking Paxlovid. she had palmarplantar dermatitis and her hands completely cleared up/ were totally smooth while/ immediately after taking the medication. The skin on her fingers had begun to peel since, but she still had better finger tips (no splits) than before. She would hope you could develop this into a prescribed medication for further use by people like her. Anti viral details: Product: COVID 19 Treatment, Brand: Paxlovid, Treatment start date=03Jul2022, Treatment stop date=08Jul2022.
Abrupt syncope with cessation of pulse and respirations at 11:15AM at main office. CPR was started by the workers present. 911 activated and code was activated by EMS and continued during transport and arrival at ER. All resuscitation efforts failed to restore breathing and cardiac activity. A large amount of blood was encountered upon intubation, so Dr. informed next of kin that cause of death was likely a large pulmonary embolus.
This spontaneous report as received from a health professional refers to mutiple patients of unknown ages. On unknown dates, the patients were vaccinated with improperly stored doses of VAQTA lot # N003194 or lot #  N005274 for prophylaxis. No adverse events were reoprted.; Sender's Comments:  US-009507513-1709USA000508: US-009507513-1709USA000505:
Extreme muscle aches, fatigue, loss of appetite. Lasted about 8 hours.
passed out; arm a little sore; feeling dizzy; A spontaneous report was received from a consumer concerning herself 70 years old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and developed passed out/loss of consciousness, arm a little sore/pain in extremity, feeling dizzy/dizziness.   The patient's medical history was not provided.  Concomitant product use was Mometasone, Anastrozole, Rosuvastatin, Vitamin D and C.   The patient received their first of two planned doses of mRNA-1273 (Batch number: 013L20A) on 10 Feb 2021 intramuscularly at left arm for prophylaxis of COVID-19 infection. The patient received their second of two planned doses of mRNA-1273 (Batch number: 030M20A) on 10 Mar 2021 intramuscularly at left arm for prophylaxis of COVID-19 infection.   On 11 Mar 2021 on the morning the patient experienced her arm was a little sore. She used her usual nasal spray with Mometasone, started feeling dizzy and within seconds she passed out. The medically significant event was loss of consciousness. Treatment information was not provided. But the other treatment included Mometasone, Anastrozole, Rosuvastatin, Vitamin D and C   Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the events passed out, arm a little sore, feeling dizzy was not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions/allergies were not reported. In March 2017, the patient was vaccinated with the improperly stored dose of PROQUAD (dose, route and anatomical location were not reported) (lot # M029595 and expiration date 10-DEC-2017) for prophylaxis.  Additionally, a propped stored sterile diluent (manufacturer unknown) (lot # and expiration date were not reported) was used to reconstitute the vaccine. There were no adverse effects reported. Administered dose of vaccine experienced the temperature excursion between 6 to 14 degrees Fahrenheit for 480 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1704USA004456: US-009507513-1704USA004454: US-009507513-1704USA004455: US-009507513-1703USA013275: US-009507513-1704USA004453:
Had fever of 100-101 for over 48 hours after getting 1st shot; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Had fever of 100-101 for over 48 hours after getting 1st shot) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Had fever of 100-101 for over 48 hours after getting 1st shot). At the time of the report, PYREXIA (Had fever of 100-101 for over 48 hours after getting 1st shot) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: high (High) fever of 100-101.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. No treatment information was reported.
After administration of the Moderna vaccine on 5/28/21, the patient reported having already previously received a Pfizer vaccine on 4/22/21. Dr. called the CDC for advice on how to proceed and was advised that we needed to report this as an adverse event. The patient has not presented any adverse signs or symptoms.
This spontaneous report as received from a other health professional refers to a patient of unknown age. On 25-JUL-2017 the patient was vaccinated with VAQTA lot # L023232 for prophylaxis. On 25-JUL-2017, 1 day after onset of therapy the patient experienced expired product administered. On an unknown date the patient experienced no adverse event. Sender's Comments: US-009507513-1709USA003130: US-009507513-1709USA003273.
Patient was give 0.25ml (not the full 0.5ml that she was supposed to receive). I got the recommended info from Moderna to complete the vaccine.
03:00 PM Lightheadedness 09:00 PM chills, fever 99.6, shakes, sweats, generalized aches and headache
received only the suspension portion; received only the suspension portion; This case was reported by a nurse via call center representative and described the occurrence of inappropriate dose of vaccine administered in a 59-year-old male patient who received Herpes zoster (Shingrix) (batch number b4z44, expiry date 27th January 2023) and (batch number de9LR, expiry date 27th January 2023) for prophylaxis.   On 28th October 2021, the patient received the 1st dose of Shingrix. On an unknown date, the dose was an unknown dose. On 28th October 2021, unknown after receiving Shingrix, the patient experienced inappropriate dose of vaccine administered and inappropriate preparation of medication. On an unknown date, the outcome of the inappropriate dose of vaccine administered and inappropriate preparation of medication were unknown  Additional details were reported as follows:  The nurse stated that the patient received only the suspension portion of Shingrix, not the antigen which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter consented to follow up.
Gross Hematuria four or five times over the following twelve days. Another two plus weeks have passed since then, with no further Hematuria.
The day after vaccination, a golf ball size lump appeared on my forearm that was red and itchy. This persisted for 7 days post vaccination.
Information has been received from a physician concerning a 14 month old female with a history of urinary tract infection and no known drug reactions/allergies who on 16-APR-2008 was vaccinated SC with a 0.5 mL dose of MMR II (lot # 656949/1310U). Secondary suspect therapy included a dose of VARIVAX (lot # 659000/1491U). The patient was seen on 22-APR-2008 in the physician's office for urticaria. A strep test on 22-APR-2008 was negative. No further information is available.
The first reaction - 15 minutes after the vaccine - I felt really dizzy and loopy. She told me, I think you better sit back down. I felt better after sitting there for 30 minutes after. I didn't get dizzy again. I finished my workday. Next morning, I woke up with a fever 100.8 (about). I woke up with sore muscles - I tend to get sore muscles easily but I felt more sore than normal and I had a headache. Fever stopped after 24 hours. Note: I also get dizzy really easily - and so it isn't difficult for something to make me dizzy.  I also felt really tired. And over the weekend, I felt nauseated (not initially but over the weekend.) And that lasted until about midday Monday (over the weekend) to be getting better . I took Tylenol and I rested. That helped with the symptoms.
Pt received vaccine at 5 PM. Went home after 15 min observation. Returned to school at 6 PM with c/o fever, chills and numbness of both arms. TYLENOL administered 320 mg PO for temp 103.8. Transported via Rescue.
3MAR upset stomach; arm 2" x 1", t98, arm hurts when moved;